Skip to content Skip to footer
Subscribe Now
Spotlight Interview_Rahul Mittal
EVENTS

Reuters Pharma USA 2025: Post-Conference Talks featuring Rahul Mittal

Brimming with insightful panel discussions, presentations on disruptive technologies, and illuminating real-world evidence shaping the healthcare landscape now and then, the two-day Reuters event celebrated pharmaceutical innovation and fresh perspectives pouring into the interactive sessions. In the panel discussion at Reuters Pharma USA 2025, Rahul Mittal outlined ways to enhance patient centricity and engagement. Rahul…
March 31, 2025

Read more

CXO TALKS

CXO Talks: Heba Nowyhed from Arcellx in a Candid Conversation with PharmaShots

CAR T-cell therapies hold a promising foothold in addressing unmet healthcare needs. Arcellx, a clinical-stage biotech company, is steadfastly exploring the potential of cell therapy in RRMM and generalized myasthenia gravis patients with its lead asset anito-cel. During presentations at ASH, anito-cel demonstrated no delayed neurotoxicity in both P-1 and pivotal P-II clinical trials for multiple myeloma.…
March 28, 2025

Read more

Radiopharma Companies Top 20 2025
TOP 20

Top 20 Radiopharmaceutical Companies of 2025

Shots: Imaging, precision diagnostics, and targeted therapies are among the many ways radiopharmaceuticals improve patient outcomes and meet unmet healthcare needs In 2024, the global radiopharmaceuticals market was valued at $6.74B and is envisioned to grow to $13.67B by 2033, exhibiting a CAGR of 8.2% from 2024 to 2033. Lilly ranks first in our list…
March 27, 2025

Read more

Disease of the Month – Lennox-Gastaut syndrome (LGS)
INSIGHTS+

Disease of the Month – Lennox-Gastaut syndrome (LGS)

Shots:  Lennox-Gastaut syndrome (LGS) is a severe childhood-onset epileptic condition characterized by repeated seizures   Our Disease of the Month report covers epidemiology, market size, current management strategies, emerging therapeutic options, and patient advocacy groups involved in enhancing patient care. Additionally, we are highlighting the key industry players advancing treatments for LGS   For a detailed epilepsy…
March 26, 2025

Read more

New Drug Designations - February 2025
INSIGHTS+

New Drug Designations – February 2025

Shots:     PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA   The February 2025 report covers designations granted to 53 drugs and 4 medical devices, spanning 16 small molecules, 14 biologics, 18 cell and gene therapies & 4 medical devices among…
March 25, 2025

Read more

ThoughtSpot_Evans James
THOUGHTSPOT

Gynecomastia Surgery: A Strategic Advancement in Men’s Health and Confidence

A Growing Conversation in Men's Health As the conversation around men’s health continues to evolve, surgical procedures once viewed as cosmetic are now being recognized for their clinical value and impact on quality of life. One such procedure is gynecomastia surgery. It is gaining attention among healthcare professionals, patients, and wellness-focused brands alike. …
March 25, 2025

Read more

Viewpoints_Anabela Cardoso_Mark Genovese
VIEWPOINTS

Lilly at ACG 2024: Anabela Cardoso and Mark Genovese in Conversation with PharmaShots

Shots:  Lilly presented results from two long-term studies evaluating sustained efficacy in patients treated with mirikizumab for both moderately to severely active Ulcerative Colitis and Crohn’s Disease at ACG 2024  At three years, more than 80 percent of patients with moderately to severely active ulcerative colitis who were on remission sustained long-term remission and relief  …
March 24, 2025

Read more

INSIGHTS+

Know Your Investor: Perceptive Advisors (March’25 Edition)

Shots:   The March edition highlights Perceptive Advisors, a New York-based investment firm specializing in public and private investments within the healthcare and life sciences sectors In 2024, Perceptive Advisors invested approximately $5.81B in 44 companies through six funding rounds, including private and debt financing For the complete report, reach out to us at connect@pharmashots.com  With…
March 20, 2025

Read more

Viewpoints_Uwe Gudat
VIEWPOINTS

Biocon Biologics at AAO 2024: Uwe Gudat in an Invigorating Discussion with PharmaShots

Shots: At the American Academy of Ophthalmology (AAO 2024), Biocon Biologics announced promising results from the extension study of its proposed biosimilar to aflibercept, MYL-1701P The study demonstrated comparable safety, efficacy, and immunogenicity between patients continuing MYL-1701P and those who switched from aflibercept to MYL-1701P Biocon Biologics' Chief Medical Officer, Uwe Gudat, discusses the groundbreaking…
March 17, 2025

Read more

Load more